Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. The firm developed a platform that enables the oral delivery of injectable proteins and large molecules. Entera Bio candidates are EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism. Both EB613 and EB612 are oral formulations of human parathyroid hormone (1-34), or Parathormon (PTH). The products are administered via injection.
Follow-Up Questions
Entera Bio Ltd 的 CEO 是谁？
Ms. Miranda Toledano 是 Entera Bio Ltd 的 Chief Executive Officer，自 2018 加入公司。
ENTX 股票的价格表现如何？
ENTX 的当前价格为 $2.56，在上个交易日 increased 了 9.06%。
Entera Bio Ltd 的主要业务主题或行业是什么？
Entera Bio Ltd 属于 Biotechnology 行业，该板块是 Health Care
